TEVA PHARMACEUTICAL INDUSTRIES LIMITED Repayments of Accounts Receivable Securitization
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Repayments of Accounts Receivable Securitization of $4.51 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfAccountsReceivableSecuritization · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED repayments of accounts receivable securitization for fiscal 2025 was $4.51B, a 5.35% decline from fiscal 2024.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED repayments of accounts receivable securitization for fiscal 2024 was $4.77B, a 9.23% increase from fiscal 2023.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED repayments of accounts receivable securitization for fiscal 2023 was $4.37B, a 6.43% decline from fiscal 2022.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED repayments of accounts receivable securitization for fiscal 2022 was $4.67B, a 9.45% decline from fiscal 2021.
| Period end | Repayments of Accounts Receivable Securitization 12 month | Repayments of Accounts Receivable Securitization 12 month as first filed |
|---|---|---|
| 2025-12-31 | $4.51B 10-K · filed 2026-02-03 | |
| 2024-12-31 | $4.77B 10-K · filed 2026-02-03 | |
| 2023-12-31 | $4.37B 10-K · filed 2025-02-05 | |
| 2022-12-31 | $4.67B 10-K · filed 2024-02-12 | |
| 2021-12-31 | $5.15B 10-K · filed 2023-02-10 | |
| 2020-12-31 | $4.61B 10-K · filed 2022-02-09 | |
| 2019-12-31 | $4.85B 10-K · filed 2021-02-10 | |
| 2018-12-31 | $5.15B 10-K · filed 2020-02-21 | |
| 2017-12-31 | $4.86B 10-K · filed 2019-02-19 | |
| 2016-12-31 | $3.66B 10-K · filed 2018-02-12 | -$3.66B 20-F · filed 2017-02-15 |
| 2015-12-31 | -$3.53B 20-F · filed 2017-02-15 | $3.53B 20-F · filed 2016-02-11 |
| 2014-12-31 | $4.20B 20-F · filed 2016-02-11 | -$4.20B 20-F · filed 2015-02-09 |
| 2013-12-31 | -$3.63B 20-F · filed 2015-02-09 | |
| 2012-12-31 | -$3.39B 20-F · filed 2014-02-10 |